Sanofi stock holds near support as RBC starts coverage with EUR 80 target

Published on 09/11/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 74.13 on Euronext Paris on September 9, 2026 after RBC Capital began coverage with an EUR 80.00 price target. The shares remain roughly 10.4 percent lower year to date but sit above chart support around EUR 72.49.

Fotorealistisches TV-Studio mit Kameras, Lichtern und Nachrichtendesk in Paris — Vivendi SE (FR0000127771) betreibt Medienstudios; dieses Bild zeigt ein realistisches TV-Studio mit Kameratechnik und Regie, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000127771) traded at EUR 74.13 on Euronext Paris on September 9, 2026, modestly below the prior close of EUR 74.70 and leaving the shares down about 10.4 percent since the start of the year, according to data relayed from Euronext Paris by Zonebourse on that date.

RBC starts coverage with EUR 80 target

As MarketScreener summarized on September 11, 2026, analysts highlight that Sanofi shares are testing a support area around EUR 72.49, with technical commentary pointing to an entry level around EUR 73.70 and a target price near EUR 79.00 for short-term traders.

According to an overview cited by MarketScreener on September 11, 2026, RBC Capital has initiated coverage of Sanofi with a Sector Perform rating and an EUR 80.00 price target, positioning its view in the lower part of a broader analyst target range that currently clusters between roughly EUR 80.00 and EUR 100.00 for the stock.

Price performance and 52-week range

Per the Euronext Paris snapshot relayed by Zonebourse on September 9, 2026, Sanofi shares closed at EUR 74.70 on September 8, 2026 and then traded at EUR 74.13 during the following session, marking a 0.76 percent decline on the day and leaving the stock down about 3.9 percent over the preceding five trading days and roughly 10.4 percent year to date.

The same Zonebourse-based data set for Sanofi on Euronext Paris indicates that the stock trades under the SAN ticker and, at the latest snapshot of September 9, 2026, remained moderately above a cited support zone around EUR 72.49, while still some distance below analyst average targets that imply upside into the upper EUR 70s and lower EUR 80s, according to the technical commentary on MarketScreener.

Fundamental backdrop and analyst context

In its technical and fundamental profile of Sanofi published on September 11, 2026, MarketScreener points to strong fundamentals, noting that more than 70 percent of companies have a weaker mix of growth, profitability, debt and visibility based on its scoring framework.

The same analysis highlights that Sanofi’s EBITDA-to-sales ratio is relatively high, resulting in robust margins before depreciation, amortization and taxes, and that the company’s earnings multiples appear attractive with a current-year price-to-earnings ratio around 11.82, which places the shares at a discount versus many global pharmaceutical peers, according to the MarketScreener commentary dated September 11, 2026.

MarketScreener also underscores that Sanofi benefits from positive cash flows, a relatively low enterprise-value-to-sales ratio and high dividend expectations compared with sector peers, while at the same time warning that consensus earnings estimates from Standard & Poor’s analysts have been revised downward over the past four months and that the average analyst recommendation leans toward underperform or sell.

Upcoming earnings and secondary listing signal

On the secondary Stuttgart exchange listing under the SNW.SG symbol, Sanofi’s shares were quoted at EUR 73.65 as of 2:31 p.m. Central European Time on September 11, 2026, down 0.20 percent from the previous close of EUR 73.80 and within a 52-week range between EUR 71.32 and EUR 90.85, according to price data from Yahoo Finance.

The same Yahoo Finance overview for SNW.SG shows an indicated earnings date of October 30, 2026 for Sanofi, which investors can treat as the next scheduled reporting checkpoint for the group’s financial results, giving the market several weeks during which sentiment will likely be steered primarily by analyst revisions and sector moves rather than fresh company-reported figures.

Sanofi stock near support ahead of next results

With Sanofi stock changing hands at EUR 74.13 on Euronext Paris as of September 9, 2026 and at EUR 73.65 on Stuttgart as of September 11, 2026, the shares are currently trading only a few euros above the EUR 72.49 support area cited in the MarketScreener technical note, while remaining well below the 52-week high of EUR 90.85 on the Stuttgart listing, a setup that leaves room for upside if RBC’s EUR 80.00 target and broader analyst expectations prove accurate.